Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7290142 | 1.00 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7300326 | 1.00 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7301555 | 1.00 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7301517 | 1.00 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7292830 | 1.00 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7292724 | 1.00 | ADORA1 (0.64) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7303349 | 0.99 | ADORA1 (0.65) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7301958 | 0.96 | ADORA1 (0.66) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL5499236 | 0.93 | ADORA1 (0.62) | ADORA1IGF1RMAPK1MAPK3MAPK14 | |
| SCHEMBL7301948 | 0.87 | ADORA1 (0.59) | ADORA1IGF1RMAPK1MAPK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0497258-B1 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-0467248-B1 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5338743-A | Pancreatitis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | disclosed |
| US-5204346-A | Cognition activators; analgesics; antidepressants; vasodilation; cardiovascular and urogential disorders; | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-20 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0467248-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |